Inicio > Psiquiatría > Utilidad de la Memantina en el tratamiento de la esquizofrenia > Página 3

Utilidad de la Memantina en el tratamiento de la esquizofrenia

14. Cropley, V. L. et al. (2006). Molecular imaging of the dopaminergic system and its association with human cognitive function. Biological Psychiatry, 59, 898-907.

15. Lewis, D. A. y Levitt, P. (2002). Schizophrenia as a disorder of neurodevelopment. Annual Review of Neuroscience, 25, 409-432.

16. Coyle, J. T. et al. (2003). Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Annals of the New York Academy of Sciences, 1003, 318-327.

17. Flaum, M. et al. (1995). Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia. American Journal of Psychiatry, 152, 704-714.

18. Garcia M. y Arango C. (2010). Neuroimagen y Neurofisiología de la Esquizofrenia. In J Vallejo y C.Leal (Eds.), Tratado de Psiquiatría (pp. 1029-1044). Barcelona: Ars Médica.

19. Goff, D. C. y Wine, L. (1997). Glutamate in schizophrenia: clinical and research implications. Schizophrenia Research, 27, 157-168.

20. Javitt, D. C. y Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry , 148, 1301-1308.

21. Grace, A. A. (1991a). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience, 41, 1-24.

22. Grace, A. A. (1993). Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. Journal of Neural Transmission. General Section, 91, 111-134.

23. Laruelle, M. et al. (2003). Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Annals of the New York Academy of Sciences, 1003, 138-158.

24. Stephan, K. E. et al. (2006). Synaptic plasticity and dysconnection in schizophrenia. Biological Psychiatry, 59, 929-939.

25. Tsai, G. y Coyle, J. T. (2002). Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology and Toxicology., 42, 165-179.

26. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18 (Suppl 1): S23-32.

27. S, Singh V Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia CNS Drugs 25(10):859-885, 2011

28. Rogawski MA, Wenk GL. The neuropharmacological basis for the useof memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003; 9: 275-308

29. Erdö SL, Schafer M. Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 1991; 198: 215-7.

30. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993; 33: 403-7.

31. Heim C, Sontag KH. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm Suppl 1995; 46: 117-30.

32. Keilhoff G, Wolf G. Memantine prevents quinolinic acid-induced hippocampal damage. Eur J Pharmacol 1992; 219: 451-4.

33. Marvanova M, Lakso M, Pirhonen J, Nawa H, Wong G, Castren E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001; 18: 247-58.

34. Elizagarate E, Sánchez P, Ojeda del Pozo, Ezcurra J, Mendiola N, Npal O, Peña J, Larumbe J, Investigación Comisionada. Victoria-Gasteiz. Departamento de sanidad y Consumo, Gobierno Vazco, 2012. Informe Nº Osteba D-12-04.

35. Rands DS. Memantine as a neuroprotective treatment in sxhiphrenia. Br J Psychiatry. 2005; 186-77; author reply 77-8.

36. Thomas C, Carroll BT, Maley RT, Jayanti K, Koduri A. Memantines and catatonic schtzophenia. Am J Psychiatry. 2005; 162(3);626.